Last deal

$41.5M

Amount

Series B

Stage

28.11.2023

Date

3

all rounds

$166.5M

Total amount

date founded

Financing round

General

About Company
Aro Biotherapeutics is a biotech company developing tissue-targeted genetic medicines.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2017

Number of employees

Company Type

For Profit

Last funding type

Series B

IPO status

Private

Description

Based in Philadelphia, Aro Biotherapeutics is using a proprietary protein technology called Centyrins to develop a new protein drug platform. Centyrins are small, non-antibody protein scaffolds that can be expressed as multi-specifics with novel therapeutic mechanisms of action. This platform is designed to achieve better efficacy and safety profiles for patients with cancer and other serious diseases. Centyrins are also ideal for the targeted delivery of complex drug payloads, including nucleic acids. The company is developing a pipeline of Centyrin-based therapeutic candidates and working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases.
Contacts
Similar Companies
1000
Kymera Therapeutics

Kymera Therapeutics

Kymera Therapeutics is a biotech company specializing in targeted protein degradation.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Cambridge, MA, USA

total rounds

7

total raised

$879M
Biond Biologics

Biond Biologics

Biond Biologics is an Israeli biotech company focused on cancer immunotherapy and autoimmune disorders.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Misgav Regional Council, Israel

total rounds

2

total raised

$32M
Sonnet BioTherapeutics

Sonnet BioTherapeutics

Sonnet BioTherapeutics is a biotechnology company that develops innovative targeted biologic drugs using its proprietary FHAB™ technology.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care

Location

Princeton, NJ, USA

total rounds

4

total raised

$50.3M
Orum Therapeutics

Orum Therapeutics

Orum Therapeutics is a private biotech company developing therapeutic antibodies to target cytosolic proteins for cancer and rare diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Daejeon, Jeong-dong, Daejeon, South Korea

total rounds

5

total raised

$92M

Financials

Funding Rounds
4
3

Number of Funding Rounds

$166.5M

Money Raised

Their latest funding was raised on 28.11.2023. Their latest investor Cowen Healthcare Investments. Their latest round Series B

Date 
Funding Round 
Investors 
Money Raised 
Lead 

Cowen Healthcare Investments

Cowen Healthcare Investments is a financial services firm offering asset management and investment banking.

Sector

Investment Banking and Brokerage Services

Subsector

Diversified Financial Services

Location

New York, NY, USA

count Of Investments

55

count Of Exists

4

Cowen Healthcare Investments

Cowen Healthcare Investments is a financial services firm offering asset management and investment banking.

Sector

Investment Banking and Brokerage Services

Subsector

Diversified Financial Services

Location

New York, NY, USA

count Of Investments

55

count Of Exists

4
Northpond Ventures

Northpond Ventures

Northpond Ventures is a science-driven venture capital firm.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

Bethesda, MD, USA

count Of Investments

112

count Of Exists

4

Cowen Healthcare Investments

Cowen Healthcare Investments is a financial services firm offering asset management and investment banking.

Sector

Investment Banking and Brokerage Services

Subsector

Diversified Financial Services

Location

New York, NY, USA

count Of Investments

55

count Of Exists

4
Co-Investors
Investors
10
4

Number of lead investors

10

Number of investors

Investor 
Lead 
Round 
Partners 
Yes
Series A, Series B
No
Series A, Series B
No
Series B

Cowen Healthcare Investments

Cowen Healthcare Investments is a financial services firm offering asset management and investment banking.

Sector

Investment Banking and Brokerage Services

Subsector

Diversified Financial Services

Location

New York, NY, USA

count Of Investments

55

count Of Exists

4
HealthCap

HealthCap

HealthCap is a venture capital firm that invests in life sciences globally.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Financial Services, Health Care, Venture Capital

Location

Stockholm, Sweden

count Of Investments

96

count Of Exists

14

BVF Partners

BVF Partners is a US-based venture capital firm that specializes in investing in small-cap biotechnology companies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Financial Services, Venture Capital, Biotechnology

count Of Investments

19

People

Founders
2
Susan Dillon
Susan Dillon

Susan Dillon

Sue Dillon, PhD, brings 30 years of experience in executive leadership roles at pharmaceutical and biotech companies to Aro Biotherapeutics. During her more than 16 year career at Johnson & Johnson, Sue led global Immunology R&D, and achieved numerous regulatory approvals for innovative antibody products for autoimmune diseases including REMICADE®, SIMPONI®, STELARA® and TREMFYA®. She also built a robust Immunology development portfolio through internal discovery and external licensing, and championed research into the emerging areas of the microbiome and immune repertoire profiling. Multi-disciplinary teams under Sue’s leadership were twice recognized with the Prix Galien Award for PROMACTA® and STELARA®, each first-in-class medicines. Sue received her PhD in Immunology from Thomas Jefferson University in Philadelphia and completed a postdoctoral fellowship in Immunology at Duke University. She was named by FierceBiotech as one of the “Top Women in Biotech” in 2013.

current job

Aro Biotherapeutics
Aro Biotherapeutics

organization founded

1

Susan Dillon

Karyn O’Neil
Karyn O’Neil

Karyn O’Neil

Karyn O’Neil has more than 30 years of experience in peptide, antibody and protein engineering. As the Venture Leader for Centyrex, a Johnson & Johnson Venture, Karyn focused on designer protein platform technologies. She is co-inventor on the Centyrin patents and has led the team advancing the Centyrin platform since its inception. She joined Centocor/Johnson & Johnson in 2001 where, prior to working on Centyrins, she held positions of increasing responsibility, ultimately becoming a Director of Antibody Therapeutics. There she played a leadership role in the discovery and optimization of multiple clinical candidates. Prior to Johnson & Johnson, Karyn was in the Applied Biotechnologies group at DuPont Pharmaceuticals. Karyn received her PhD from the University of Pennsylvania where she focused on protein engineering and protein biophysics. She has authored more than 55 publications and holds over 30 patents. Karyn also serves as an editor for Protein Engineering, Design and Selection.

current job

Aro Biotherapeutics
Aro Biotherapeutics

organization founded

1

Karyn O’Neil

Employee Profiles
6

Sukumar Sakamuri

Chief Technology Officer

Scott Greenberg

Chief business officer

Derek Miller

Derek Miller

Chief Business Officer & Head of Corporate Strategy

Karyn O’Neil

Karyn O’Neil

Co-founder and Chief Scientific Officer

Susan Dillon

Susan Dillon

Co-founder, President and Chief Executive Officer

Mark Laurenzi

Mark Laurenzi

Vice President of Finance and Operations

Activity

Recent News
4
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

month